Blocking the action CTLA-4 and PD-1 receptors or their ligands by mAbs is effective in treating a number of different tumors including melanoma, NSCLC, bladder cancer, renal cancer, cancers with mismatch repair enzyme deficiency, and Hogkin’s lymphoma [124]. Here, CTLA4 is linked to cancer.